Deciphering the recurrence-associated coding and non-coding genes in triple-negative breast cancer through genomic and transcriptomic profiling
Abstract
Breast cancer exhibits significant molecular heterogeneity, with triple-negative breast cancer (TNBC) being the most biologically complex subtype, having a higher probability for recurrence and presenting greater clinical challenges. The increased mortality rate of BC patients in India might be linked to a higher prevalence of TNBC. In this study, transcriptome analysis of 24 breast tumor tissues and their corresponding adjacent tissues was conducted to understand the differential expression profile of the study cohort, which revealed 9,049 significantly differentially expressed genes (DEGs). To identify TNBC recurrence-specific molecular alterations, whole-exome sequencing and transcriptomic analyses of representative 4 recurrent and 4 non-recurrent TNBC patients were performed. The expression data identified a total of 913 DEGs in recurrent TNBC patients. Gene Set Enrichment Analysis (GSEA) of the identified DEGs in recurrent TNBC revealed enrichment in key biological pathways that facilitate tumor growth, proliferation, stemness, and cancer progression. Network analysis of protein-coding DEGs identified key recurrence-associated hub genes. Furthermore, the identified hub genes, CKAP2L, KIF1A, KIF4A, KIF14, and MYL4 were analyzed by using Kaplan-Meier Plotter based on TCGA-TNBC dataset, which revealed poor patient survival due to their elevated expression in recurrent-TNBC patients. In contrast, lower expression levels of CNTNAP2, MYL7, SNAP25, LTF, and PDCD1 showed the worst survival. Additionally, two non-coding RNAs, miR-635 and miR-647, with increased expression levels, were identified in recurrent TNBC patients. These findings highlight recurrence associated molecular pathways and gene signatures encompassing both coding and non-coding elements underscoring their potential utility as prognostic and diagnostic biomarkers in patients with recurrent triple negative breast cancer.